Major surface protein 2 (MSP-2), identified as a protection-inducing immunogen against Anaplasma marginale challenge, is an immunodominant outer membrane protein with orthologues in all examined Anaplasma species. Although immunization with live Anaplasma centrale has long been used to induce protection against acute disease upon challenge with virulent A. marginale, its MSP-2 structure and whether MSP-2 variants are generated during persistence of the vaccine strain was unknown. In this study, we showed that the A. centrale vaccine strain persisted for a minimum of 4 years postvaccination and generated sequential MSP-2 variants. ؉ -T-cell epitopes between these two genetically distinct Anaplasma species indicates that they present a similar repertoire of MSP-2 epitopes to the immune system and that this similarity may be responsible for all or part of the A. centrale vaccine efficacy.
The identification of Anaplasma marginale as a specific infectious pathogen of cattle in 1908 was the first description of what are now recognized as ehrlichiae (28, 29) . Remarkably, within 4 years of this initial description, Sir Arnold Theiler described the use of a related organism, Anaplasma centrale, as a live vaccine to minimize the severity of A. marginale infection (30) . In experiments carried out from 1909 to 1911, Theiler described the need to establish an A. centrale infection and allow recovery from this mild form of the disease prior to field exposure to ticks carrying A. marginale (30) . Furthermore, he established that A. centrale vaccination did not prevent A. marginale infection upon challenge but rather resulted in lower levels of A. marginale rickettsemia and a reduction in severity of clinical signs compared to unvaccinated controls. Based on these findings, A. centrale live vaccines were used to protect cattle imported from England to South Africa in 1909 and have since remained in use in tropical and subtropical regions (15, 24, 25, 33) .
Current mechanistic understanding of immunity to A. marginale has been derived both from experimental vaccine trials, which identified major surface protein 2 (MSP-2) as a protection-inducing immunogen (22) , and from the study of infection-induced immunity. After recovery from acute A. marginale infection, during which rickettsemia levels exceed 10 9 organisms per ml, cattle remain persistently infected but are immune to high-level rickettsemia and disease if subsequently challenged with homologous or heterologous strains (15, 23) . Persistent infection is asymptomatic and characterized by cyclic waves of rickettsemia (12) , with each cycle reflecting the emergence and replication of A. marginale organisms expressing an antigenically variant MSP-2 (8, 9, 20) . Analysis of A. marginale MSP-2 antigenic variants has revealed highly conserved amino and carboxy-terminal regions with the central one-third of the protein being hypervariable (7) (8) (9) . This central region represents the primary surface domain and encodes the immunodominant but hypervariable B-cell epitopes (7) (8) (9) . In contrast, the conserved flanking regions are rich in T-cell epitopes and induce strong recall CD4
ϩ -T-cell responses against MSP-2 regardless of the variation in the central surface domain (3, 5) . This conserved anamnestic T-cell response is postulated to provide rapid T-cell help for primary B-cell responses to the hypervariable surface epitopes and control the emergent variants prior to reaching the high rickettsemia levels responsible for clinical disease (3, 20) . This role for the conserved T-cell epitopes is supported by the rapid generation of variant-specific immunoglobulin G2 antibody after emergence of a new MSP-2 variant and the control of rickettsemia during persistent A. marginale infection to levels 100 to 1,000 times below the threshold for clinical disease (4, 8, 9) . Does Theiler's A. centrale vaccine work by mimicking natural persistent infection? If this is correct, A. centrale should persist in vaccinates and generate MSP-2 variants that mimic the antigenic structure of those expressed by A. marginale. Specifically, this would comprise a diverse set of MSP-2 central extracellular domains and highly conserved flanking regions /BOX_form.html) were used. The GenBank accession numbers for the A. centrale msp-2 transcripts are AY040556 to AY040563.
Southern blot detection of genomic A. centrale msp-2 and the msp-2 expression site. DNA was extracted from 10 9 A. centrale and from the South Idaho strain of A. marginale and digested by using FspI as previously described for A. marginale (1) . After electrophoresis on a 0.7% agarose gel and transfer to a nylon membranes by standard techniques, the membrane was hybridized sequentially with each of three probes: (i) full-length orf4 from the expression site, (ii) msp-2 (bp 375 to 965), and (iii) the 5Ј terminus of msp-2 (bp 2 to 335). The probes were generated by PCR by using the following corresponding primer sets: (i) for orf4, 5Ј-TTGCACACACTACCCTCTTC and 5Ј-GCCGCTACATAGAGCTCACCC; (ii) for msp-2, 5Ј-TGGAGGAGCAAGGGTTGAAGT and 5Ј-TTACCACCGA TACCAGCACAA; and (iii) for the 5Ј terminus msp-2, 5Ј-TGAGTGCTGTAA GTAATAGG and 5Ј-CTATCCTTGAAGCTAATCTTGGGTTC. Labeling of the probes with digoxigenin, hybridization with DIG Easy Hyb (Roche, Inc.) overnight at 42°C, washing (twice with 2ϫ SSC [1ϫ SSC is 0.15 M NaCl plus 0.015 M sodium citrate]-0.1% sodium dodecyl sulfate at room temperature and twice in the same buffer at 60°C), and detection by enhanced chemiluminescence was done as previously described (1, 2). The filter was stripped between hybridizations with each of the probes by using two washes in 0.2 M NaOH-0.1% sodium dodecyl sulfate at 37°C for 15 min.
Peptide stimulation of MSP-2 specific CD4 ؉ -T-cell lines. The derivation and characterization of the short-term T-cell lines used in this study have been described in detail elsewhere (3) . Briefly, these T-cell lines were derived from three MSP-2-immunized calves with different class II haplotypes ( ϩ T cells by treatment with monoclonal antibody and complement (3), the cell lines were 94 to 99% CD4 ϩ T cells. Proliferation assays were conducted in replicate wells of 96-well plates by using the T-cell lines (3 ϫ 10 4 cells per well) in complete RPMI 1640 medium containing antigen and, as antigen-presenting cells, irradiated autologous peripheral blood mononuclear cells (2 ϫ 10 5 cells per well), as previously described (3) (4) (5) . The tested peptide antigens were derived from MSP-2 sequences that stimulated CD4
ϩ -T-cell lines from each of the three calves of different major histocompatibility complex (MHC) class II haplotypes (3) or else represented the polymorphic sequence identified in A. centrale during the present study. These sequences are shown in Fig. 5 . The peptides were tested at concentrations from 0.4 to 10.0 g/ml. As positive control antigens, A. marginale lysate, purified native MSP-2, and the A. marginale peptide P12 (positions 312 to 341) were tested at the same concentrations. As negative control antigens, lysates of uninfected erythrocytes or an A. marginale 30-mer peptide (P1) that does not contain a T-cell epitope (3) was tested at the same concentrations. Cells were radiolabeled during the last 18 h of a 3-to 4-day stimulation period by using 0.25 Ci of [ 3 H]thymidine, collected by using an automated cell harvester, and counted with a liquid scintillation counter. The results are presented as the mean counts per minute of replicate cultures Ϯ 1 standard deviation.
RESULTS
Persistence of the A. centrale vaccine strain. A. centrale was detected in blood obtained from each of the 10 Holstein dairy cows vaccinated 5 to 49 months earlier (Table 1 ). Blood from each of the eight vaccinates tested transmitted A. centrale upon subinoculation into individual susceptible, seronegative calves 1A) and secondary (Fig. 1B) structure of the encoded MSP-2 is common between the A. centrale vaccine strain and A. marginale. While overall there is 77% identity between the vaccine strain MSP-2 and A. marginale, alignment revealed that this conservation was primarily in the amino-and carboxyterminal domains (Fig. 1A) . There is 83% identity in the region from amino acids 1 to 189 between A. centrale and A. marginale and 92% identity in the region from amino acid 272 to the carboxy terminus (numbering based on 11.2 MSP-2 [21] ). The predicted membrane-spanning structure of these amino-and carboxy-terminal regions is highly conserved between A. marginale and A. centrale (Fig. 1B) . In contrast, the central extracellular domain was variable between A. centrale and A. marginale 11.2, with only 44% identity in the region between amino acids 190 and 271. This variation is generated by deletions and substitutions in A. centrale MSP-2 relative to A. marginale MSP-2 ( Fig. 1A) and does alter the predicted structure (Fig. 1B) .
Examination of a second A. centrale vaccinate, animal 410, in the acute infection after vaccination revealed two distinct fulllength msp-2 transcripts. One of these, 410A, encoded a MSP-2 very similar to that in animal 337 but the second, 410B, encoded a variant MSP-2 (Fig. 2) . Alignment of the amino acid sequences encoded by these two transcripts with the sequence from vaccinate 337 revealed absolute conservation of the amino-terminal domain, a single amino acid substitution in the carboxy-terminal domain, and a highly variable region between amino acid 181 and approximately amino acid 265 (Fig. 2) . This region corresponds to the A. marginale MSP-2 hypervariable extracellular domain (7, 8, 26) , and the changes among the A. centrale MSP-2 variants reflected insertions, deletions, and substitutions (Fig. 2) . Consistent with results from A. marginale infection in which multiple variants emerge during persistence, a total of 37 msp-2 transcripts were identified. Alignment of the encoded MSP-2 amino acid sequences revealed a predominant region of variation extending from position 197 to position 270. The identity in the hypervariable region ranged from 75 to 95% when the peak 1 and peak 2 MSP-2 types were compared. Alignment of the two most different encoded MSP-2 types from peaks 1 and 2 illustrates the substitutions, insertions, and deletions that typify the hypervariable regions (Fig. 3) . To verify that variation was consistently generated in the A. centrale vaccinates, msp-2 transcripts were sequenced from three peaks of rickettsemic cycles in vaccinated animal no. Genomic structure of A. centrale msp-2. Genomic DNA was extracted from the vaccine strain and digested with FspI to excise the entire expression site locus (1). This locus is composed of an promoter and an operon of four genes, orf4, orf3, orf2, and msp-2 (1). There are no FspI sites within this locus in either A. centrale or A. marginale. Probing the digested DNA with the orf4 probe identified the operon expression locus in A. centrale and, as previously reported (1, 2), in A. marginale (Fig.  4) . The same blot was stripped and rehybridized by using a msp-2 probe (bp 375 to 695) that includes the highly conserved region from bp 375 to 550 present in all described msp-2 genes, including the pseudogenes that lack a complete 5Ј end, as well as the expression site complete msp-2 gene (1). This second hybridization revealed multiple fragments in both A. centrale and A. marginale, a pattern previously reported for A. marginale DNA cleaved with FspI or additional restriction enzymes that cleave outside of the msp-2 coding sequence (1, 21) . In contrast to the multiple msp-2 sequences detected by the bp-375-to-695 probe, stripping and then rehybridizing with a probe representing the 5Ј terminus of msp-2 (bp 2 to 335) (Fig. 4) . This demonstrates the presence of multiple msp-2 pseudogenes, lacking the 5Ј end of full-length msp-2, in A. centrale as well as in A. marginale. There was only a single msp-2 gene complete with a 5Ј end, and this sole full-length gene was in the operon expression site defined by orf4 (Fig. 4) .
Conservation of CD4
؉ -T-cell epitopes between A. centrale and A. marginale MSP-2. Notable features of the MSP-2 structure in A. centrale and A. marginale include the hypervariable extracellular domain and the flanking amino-and carboxyterminal membrane domains (Fig. 1) . Although the aminoand carboxy-terminal domains are, in general, conserved between A. marginale and A. centrale MSP-2 (Fig. 1A) , the occurrence of amino acid substitutions in A. centrale relative to A. marginale may affect the CD4 ϩ -T-cell epitopes identified in these regions. Mapping of the CD4 ϩ -T-cell epitopes within the amino-and carboxy-terminal domains of A. marginale MSP-2 identified a minimum of four epitopes that were recognized by cattle with three different MHC class II haplotypes (3). Comparison of the sequences between A. marginale and the vaccine strain of A. centrale (Fig. 5) revealed that three of these epitopes were completely conserved and the fourth (designated P12 [3] ), represented by amino acids 312 to 341, had a single amino acid substitution in A. centrale (V3I). This 312-to-341 region contains a dominant CD4
ϩ -T-cell epitope in A. marginale MSP-2 that induces both strong proliferation and gamma interferon production (3). Stimulation of MSP-2-specific CD4 ϩ -T-cell lines with the parent P12 (312 to 341), the A. marginale P12 18 (324 to 341 peptide) represented in A. marginale, or the A. centrale P12 18 peptide with the V3I substitution found in A. centrale revealed similar proliferation (Fig. 6) . Notably, T-cell lines from each of three cattle (animals 59, 60, and 61) with different MHC class II haplotypes responded to the peptide derived from either A. marginale or A. centrale (Fig. 6 ). There were no significant differences in the proliferative responses to the P12, A. marginale P12 18 , and A. centrale P12 18 peptides by any of the T-cell lines. In addition, each T-cell line responded similarly to A. marginale P12 19 (323 to 341 peptide), A. marginale P12 20 (322 to 341 peptide), A. centrale P12 19 peptide, and A. centrale P12 20 (data not shown), indicating that the V3I substitution found in A. centrale had no effect on the epitope at either terminal or subterminal positions. All cell lines responded to A. marginale lysate (Fig.  6 ) and native MSP-2 (data not shown) but not to either a control peptide P1 (Fig. 6) or uninfected erythrocyte lysate (data not shown).
DISCUSSION
A. centrale is genetically distinct from A. marginale based upon analysis of the 16S rRNA gene sequences of both organisms (11) . The question of whether A. centrale is a subspecies of A. marginale, as originally suggested by Theiler (30) , or a separate species is unresolved (6, 11) . Nonetheless, there are clear differences in other genes, antigens, and virulence between the two organisms (14, 16, 19, 27) . The presence of a closely related MSP-2 ortholog in A. centrale is unsurprising given that both Anaplasma ovis and Anaplasma phagocytophila, the agent of human granulocytic ehrlichiosis, also contain a MSP-2 ortholog (3, 10, 17, 18, 35) . The overall structure of these MSP-2 orthologs is retained in each of these Anaplasma species-conservation in the amino-and carboxy-terminal thirds of the protein with a highly variable domain in the central extracellular domain (3, 10, 17, 18, 35) . Originally shown in A. marginale persistently infected cattle, variation is generated in this central hypervariable MSP-2 domain, while the amino-and carboxy-terminal regions are essentially invariant (3, 8, 9, 26) . The MSP-2 ortholog of A. phagocytophila demonstrates a similar pattern of variation in the central domain when strains are compared (10, 16, 35) . In the present work, we have shown that the A. centrale vaccine strain also generates sequential variation in the central domain, whereas the flanking regions are highly conserved. Comparison of the encoded MSP-2 sequences obtained during acute and persistent infection after A. centrale vaccination revealed substitutions, deletions, and insertions in the central hypervariable domain. This pattern of variation and the degree of variation, as little as 72% identity between sequential time points, is similar to the variation identified in the A. marginale central extracellular domain and has been shown to result in B-cell epitope variation (9, 10, 26) . Thus, persistence of the A. centrale vaccine strain would be expected to induce a population of B-cell responses against MSP-2 variants, including those that may cross-react with A. marginale variants. This is consistent with prior data demonstrating that cross-reactive antibody from persistent infection, resulting from infection with either the A. centrale vaccine strain or A. marginale, is primarily directed at MSP-2 (19, 34) .
The amino-and carboxy-terminal thirds of MSP-2 are not identical between A. centrale and A. marginale, although they are conserved among MSP-2 variants within each species. In A. marginale this conservation is reflected by the ability of CD4 ϩ -T-cell lines and clones against these regions to recognize all strains and is consistent with the priming and continual restimulation of CD4 ϩ T cells to provide B-cell help for production of variant-specific antibody during persistent infection (3, 5) . CD4
ϩ -T-cell epitopes mapped in A. marginale MSP-2 include four that are recognized by T cells of cattle with three different MHC class II haplotypes (3) . Three of these epitopes are within sequences that are identical between A. centrale and A. marginale (amino acids 141 to 170, 292 to 321, and 332 to 361), while the variation in the fourth (amino acids 312 to 341) was represented by a single amino acid substitution at position 324 that did not alter the epitope. This epitope conservation suggests that A. marginale challenge would stimulate recall responses in A. centrale-vaccinated cattle. In contrast, the polymorphic region from amino acid positions 19 to 41 in the amino terminus, in which 12 of 23 residues differ between A. centrale and A marginale (Fig. 1A) , does not appear to contain a CD4
ϩ -T-cell epitope recognized by any of the MHC class II alleles represented in the calves (3). There are some CD4
ϩ -T-cell epitopes in the amino-and carboxy-terminal thirds that map to sequences that are polymorphic between A. centrale and A. marginale, e.g., the 30-mer peptide representing amino acid positions 372 to 401. This peptide, recognized by CD4 ϩ -T-cell lines from some but not all of the MHC class II haplotypes (3), has eight substitutions in A. centrale relative to A. marginale (Fig. 1A) . Whether multiple conserved CD4
ϩ -T-cell epitopes would be sufficient to trigger protective recall responses even though other CD4
ϩ -T-cell epitopes are polymorphic is an intriguing question but has not yet been addressed.
A. marginale MSP-2 variants are generated by the recombination of pseudogenes, each composed of the hypervariable domain flanked by segments of the conserved 5Ј and 3Ј regions, into a single expression site (1, 2) . The expression site itself is an operon composed of a single promoter followed by four open reading frames: orf4, orf3, orf2, and finally msp-2 (1, 2). Consistent with a conserved pattern of MSP-2 variation, A. centrale maintains this genomic structure with multiple msp-2 pseudogenes but with only a single full-length msp-2 gene that maps to the orf4-bearing expression site. Amplification and sequencing of this msp-2 expression site locus in A. centrale (data not shown) identifies the presence of the promoter, orf4, orf3, and orf2 as predicted.
The efficacy of A. centrale vaccination is dependent upon actual infection of the recipient and cannot be reproduced by inoculation with killed whole organisms. This is consistent with the need to generate sequential MSP-2 variants during infection and to induce both a population of variant-specific B cells and CD4
ϩ T cells to conserved epitopes capable of controlling the high-level rickettsemia upon A. marginale challenge. The efficacy of this vaccine regimen, now in use for more than 90 years, suggests that strategies to mimic these induced immune responses are a key to development of an effective, non-bloodbased vaccine.
FIG. 6. Conservation of MSP-2 CD4
ϩ -T-cell epitopes between A. marginale and the A. centrale vaccine strain. MSP-2-specific cell lines from each of three calves (A, animal 59; B, animal 60; and C, animal 61) were stimulated with a 30-mer peptide representing A. marginale MSP-2 amino acids 312 to 341 (Am P12) previously shown to contain a CD4 ϩ -T-cell epitopes (3), an 18-mer peptide representing A. marginale MSP-2 amino acids 324 to 341 (Am P12 18 ), an 18-mer peptide representing the same region but with a single amino acid substitution in A. centrale MSP-2 (Ac P12 18 ), or a 30-mer peptide representing an A. marginale sequence that does not contain a T-cell epitope (P1 [3] ). All peptides were tested over a concentration range of 0.4 to 10 g per ml. The results are presented as mean counts per minute of replicate cultures Ϯ 1 standard deviation.
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